Organisation paid for research Program year 2021 Source: CMS Open Payments

Adobe Gastroenterology

Neither a doctor nor a teaching hospital

Research payments

$163,107

43 payments

Through program year 2021, Adobe Gastroenterology is reported as receiving $163,107 in research payments, across 43 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$54,017	16
2020	Research	$98,844	23
2019	Research	$10,247	4

Breakdown

Who paid Research payments · program years 2019–2021

Allergan Inc. $163,107 43 payments

Studies the money was for Research payments · program years 2019–2021

AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $73,764 11 payments
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $31,754 6 payments
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) $25,080 12 payments
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) $22,263 10 payments
Open-Label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis Nash $7,315 3 payments
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $2,932 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.